This story is one of two we are reviewing that focuses on FDA’s approval of a drug designed to speed patient recovery from flu symptoms (the second story is from ABC News). The drug is baloxavir marboxil, marketed under the trade name Xofluza. This New York Times story hits most of the points that we want to see in a story about a new drug.
The criteria that we use at HealthNewsReview.org to review health-related news stories were not developed in a vacuum. Rather, these are the criteria we feel are essential to allow patients and health care providers to make informed decisions about diagnosis and treatment options. While we do ding it on a couple things, the story does not exaggerate the findings, and provides people with the fundamental details they need to be informed patients.
We were especially pleased that this story did not perpetuate misinformation that’s developed around this drug — that is, that it could help reduce transmission of the virus. To date, there is no evidence to show that as a benefit.
The story devotes its second paragraph to cost, including how that cost may differ depending on whether patients have insurance. Well done.
This is a really close one. The story does a lot of things well here. It notes that, in one trial, there was no difference in the benefits between Xofluza and existing flu treatment drug oseltamivir (better known as Tamiflu). However, it does not actually quantify the benefits associated with Xofluza. Instead, the story states that it “may alleviate some symptoms and shorten the time patients feel sick.”
We approve of the cautious language used throughout the story, but we like to see quantified benefits in instances where the information is available. In this case, an article published in the New England Journal of Medicine in September reported that Xofluza reduced the “time to alleviation of symptoms” by a mean of 25-38 hours, compared to placebo (the difference depended on the age group of the patient). Ergo, a not satisfactory rating here.
The story addresses this issue head on, earning it a solid satisfactory rating from us. One point that would have made it even stronger would have been to note that the company selling Xofluza warns that pregnant women and nursing mothers may want to avoid the drug, as it is not known whether the drug may harm the fetus or if it would pass into breastmilk for nursing mothers.
The story does a good job of describing the supporting evidence clearly and concisely.
No disease mongering here. In fact, the story provides good context on the risks posed by influenza.
The story incorporates input from two sources at the FDA, but the information appears to stem from an FDA statement. Information from pharmaceutical companies is clearly marked, but we really look for news stories to incorporate input from independent sources — beyond what may be available in a news release.
The story addresses the similarities (and differences) to other drugs that address flu symptoms, particularly oseltamivir (Tamiflu).
The story notes that Xofluza has received FDA approval.
As noted above, the drugs similarities and differences to existing pharmaceutical treatment options was laid out clearly. The news peg here was FDA’s approval of the drug, which is also made clear.
The work goes well beyond what you would find in any news release. We particularly applaud the story’s discussion of viruses developing resistance to antiviral drugs.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like